Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback